Greater Cannabis Company (GCAN) Non-Current Assets (2018 - 2024)
Greater Cannabis Company's (GCAN) quarterly Non-Current Assets came in at $417.0 in Q4 2024, down 92.3% year-on-year from $5417.0 in Q1 2024, and down 74.99% quarter-over-quarter from $1667.0 in Q3 2024.
Greater Cannabis Company (GCAN) Non-Current Assets (2018 - 2024) Analysis & Trends
Greater Cannabis Company's Non-Current Assets history runs 7 years deep, the most recent figure standing at $417.0 for Q4 2024.
- On a quarterly basis, Non-Current Assets fell 92.3% year-over-year to $417.0 in Q4 2024; TTM through Sep 2025 was $417.0, a 97.06% decrease from a year earlier, with the FY2024 full-year figure at $417.0, down 92.3% from the prior year.
- Non-Current Assets fell to $417.0 in Q4 2024 per GCAN's latest filing, from $1667.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $24167.0 in Q1 2020 and bottomed at $417.0 in Q4 2024.
- The 5-year median for Non-Current Assets is $12292.0 (2022), against an average of $12292.0.
- Across the five-year window, Non-Current Assets retreated 20.69% in 2021 and sank 92.3% in 2024, its largest moves.
- Year by year, Non-Current Assets stood at $20417.0 in 2020, then decreased by 24.49% to $15417.0 in 2021, then plunged by 32.43% to $10417.0 in 2022, then sank by 48.0% to $5417.0 in 2023, then sank by 92.3% to $417.0 in 2024.
- Per Business Quant, the three latest GCAN Non-Current Assets figures stand at $417.0 (Q4 2024), $1667.0 (Q3 2024), and $2917.0 (Q2 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 417.00 |
| Sep 30, 2024 | 1,667.00 |
| Jun 30, 2024 | 2,917.00 |
| Mar 31, 2024 | 4,167.00 |
| Dec 31, 2023 | 5,417.00 |
| Sep 30, 2023 | 6,667.00 |
| Jun 30, 2023 | 7,917.00 |
| Mar 31, 2023 | 9,167.00 |
| Dec 31, 2022 | 10,417.00 |
| Sep 30, 2022 | 11,667.00 |
| Jun 30, 2022 | 12,917.00 |
| Mar 31, 2022 | 14,167.00 |
| Dec 31, 2021 | 15,417.00 |
| Sep 30, 2021 | 16,667.00 |
| Jun 30, 2021 | 17,917.00 |
| Mar 31, 2021 | 19,167.00 |
| Dec 31, 2020 | 20,417.00 |
| Sep 30, 2020 | 21,667.00 |
| Jun 30, 2020 | 22,917.00 |
| Mar 31, 2020 | 24,167.00 |